In our case, myocarditis suddenly appeared on day 3 post-treatment of PD-L1 blockade but not in the therapeutic period of the PD-1 inhibitor combined with radiotherapy, implying that the combinatorial use of PD-1 and PD-L1 inhibitors may lead to a substantial increase of immunotherapy-induced cardiomyopathy. Here, PDCD1 is linked to myocarditis.